Table 2. First-line chemotherapy with and without cetuximab in patients with advanced NSCLC: randomized trials.
| Randomized trials | ||
|---|---|---|
| Phase II trials | ||
| LUCAS (17) | ||
| Cisplatin/Vinorelbine plus Cetuximab | Cisplatin/Vinorelbine | |
| N | 43 | 43 |
| Response rate | 35% | 28% |
| Progression-free survival | 5.0 months | 4.6 months |
| Overall survival median | 8.3 months | 7.3 months |
| 1-year | 33% | 26% |
| 2-year | 16% | 0% |
| Canadian trial (18) | ||
| Platin/Gemcitabine plus Cetuximab | Platin/Gemcitabine | |
| N | 65 | 65 |
| Response rate | 28% | 18% |
| Progression-free survival | 5.1 months | 4.2 months |
| Overall survival median | 12 months | 9 months |
| 1-year | 50% | 37.5% |
| Phase III trials | ||
| FLEX (20) | ||
| Cisplatin/Vinorelbine plus Cetuximab | Cisplatin/Vinorelbine | |
| N | 557 | 568 |
| Response rate | 36% | 29% |
| Progression-free survival | 4.8 months | 4.8 months |
| Overall survival median | 11.3 months | 10.1 months |
| 1-year | 47% | 42% |
| BMS099 (21) | ||
| Carboplatin/Taxane plus Cetuximab | Carboplatin/Taxane | |
| N | 338 | 338 |
| Response rate | 26% | 17% |
| Progression-free survival | 4.4 months | 4.2 months |
| Overall survival median | 9.7 months | 8.4 months |